Home » Doctors » Currently Reading:

When Doctors Create Their Own Evidence-Based Medicine

November 8, 2009 Doctors No Comments

By Jacob Goldstein

When Doctors Create Their Own Evidence-Based MedicineEvidence-based medicine sounds straightforward enough, but (like everything else in health care) it’s become pretty contentious. The argument against evidence-based care says, more or less, that no two patients are alike, so doctors must be flexible in their use of evidence and can’t be bound by rigid protocols based on large studies.

But Intermountain Healthcare, a network of hospitals and clinics in Utah and Idaho, has been pushing for more evidence-based care at its facilities for a while now, with some pretty interesting results.

After Intermountain figured out that about a quarter of the elective inductions of labor on its maternity wards were being done before the 39th week of pregnancy (contrary to accepted guidelines), they looked at how the babies fared — and found that those born before 39 weeks were far more likely to wind up in intensive care. When the docs saw those data, the percentage of elective inductions before 39 weeks fell sharply, an Intermountain exec told us a while back.

As it turns out, Intermountain has created a whole system for developing evidence and creating internal protocols — a system explained at some length in a story coming out in this weekend’s New York Times Magazine. One key piece is simply to start measuring how docs are performing a given procedure, to allow the staff to begin to understand variations in care and how they might be correlated with variations in outcomes.

Since developing a protocol for acute respiratory distress syndrome in the late 1980s, Intermountain has developed protocols for some 50 clinical conditions, accounting for more than half of its patients. Doctors, nurses and administrators create the protocols based on internal evidence about what works and what doesn’t. Once a protocol is in place, doctors have the option to override whatever default choices the protocol recommends.

But outcomes seem to improve after the protocols are put in place. A protocol for dealing with one a category of pneumonia cut the death rate associated with the condition by 40% over several years, the article says.

Image: iStockphoto

Comment on this Article:







Partner links

Advertising

Drugs

South Korean FDA Probes Roche for Aiding Tamiflu Stockpiling

November 8, 2009

By Shirley S. Wang Should companies be allowed to buy large quantities of medicine like Tamiflu to have on hand in case their employees develop the H1N1 flu virus? Not according to the law in South Korea, where it’s illegal for non-medical professionals to purchase big lots of drugs. Punishment is up to five years [...]

Boosting Medical Students’ Training in Drug Abuse

November 7, 2009

By Shirley S. Wang There’s lot of action these days aimed at curbing the abuse of prescription drugs. The FDA is working on a plan to make it harder for people to get access to unauthorized prescription painkillers, pain specialists have come out with guidelines to help doctors manage pain-drug-abusing patients and drug companies have [...]

What Will Pfizer’s R&D Look Like a Year from Now?

October 21, 2009

By Jonathan D. Rockoff Pfizer’s huge R&D shop is even bigger now that the company has swallowed Wyeth. To get a sense of the changes that could be in store, the Health Blog spoke today with the company’s two top R&D execs — Martin Mackay, a Pfizer veteran who will lead small-molecule work, and Mikael [...]

See Your Doctor: The Dawn of Consumer Drug Ads

October 13, 2009

By Jacob Goldstein For a look back at a key breakthrough in the history of the pharmaceutical industry, we turn now to Joe Davis, a retired ad guy who lives in Vermont. Back in the mid-1980s, Davis came up with an idea: Run a TV ad for Seldane, the allergy medicine, but don’t say the [...]

Why Other Drugmakers Want to Be More Like J&J

October 12, 2009

By Jacob Goldstein Johnson & Johnson’s third-quarter earnings, out today, provide the latest reminder of why other drugmakers want to be more like J&J. In a nutshell: It’s a tough time to be in the prescription drug business, what with stiff competition from generics manufacturers and payers pushing for lower costs on branded drugs. So [...]

Related Links

Research

What Will Pfizer’s R&D Look Like a Year from Now?

October 21, 2009

By Jonathan D. Rockoff Pfizer’s huge R&D shop is even bigger now that the company has swallowed Wyeth. To get a sense of the changes that could be in store, the Health Blog spoke today with the company’s two top R&D execs — Martin Mackay, a Pfizer veteran who will lead small-molecule work, and Mikael [...]

Are Mammograms and PSA Tests Overrated?

October 21, 2009

By Jacob Goldstein Catch cancers early and treat them before they become deadly. That’s the idea behind cancer screening, and that’s clearly how it works with pap smears for cervical cancer and colonoscopy for colon cancer. But in some cases screening can lead to aggressive treatment of slow-growing tumors that would never have caused a [...]

The Problem With Ranking Countries’ Health-Care Systems

October 20, 2009

By Jacob Goldstein The oft-cited WHO ranking that said the U.S. has the 37th best health-care system in the world is dated and had problems even when it was new, WSJ stats maven Carl Bialik writes in his column today. The ranking was published in 2000, and came up against a major problem: Good data [...]